Cargando…

Antibody-mediated cell depletion therapies in multiple sclerosis

Development of disease-modifying therapies including monoclonal antibody (mAb)-based therapeutics for the treatment of multiple sclerosis (MS) has been extremely successful over the past decades. Most of the mAb-based therapies approved for MS deplete immune cell subsets and act through activation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mariottini, Alice, Muraro, Paolo A., Lünemann, Jan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511140/ https://www.ncbi.nlm.nih.gov/pubmed/36172350 http://dx.doi.org/10.3389/fimmu.2022.953649

Ejemplares similares

Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis
por: Massacesi, Luca, et al.
Publicado: (2022)

Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances
por: Mariottini, Alice, et al.
Publicado: (2023)

Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis
por: Amoriello, Roberta, et al.
Publicado: (2021)

The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies
por: Amoriello, Roberta, et al.
Publicado: (2020)

Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies
por: Alfonso-Dunn, Roberto, et al.
Publicado: (2022)

Viral triggers of multiple sclerosis
por: Kakalacheva, Kristina, et al.
Publicado: (2011)

B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
por: Zhang, Zheng, et al.
Publicado: (2023)

Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Contribution of Dysregulated B-Cells and IgE Antibody Responses to Multiple Sclerosis
por: Seals, Malik R., et al.
Publicado: (2022)

Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party
por: Cencioni, Maria Teresa, et al.
Publicado: (2022)

Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study
por: Alfonso-Dunn, Roberto, et al.
Publicado: (2023)

The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders
por: Häusser-Kinzel, Silke, et al.
Publicado: (2019)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential
por: Keller, Christian W., et al.
Publicado: (2017)

Label-free method for anti-glucopeptide antibody detection in Multiple Sclerosis
por: Real-Fernández, Feliciana, et al.
Publicado: (2015)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
por: Clemente, Nausicaa, et al.
Publicado: (2017)

Autophagy and Autophagy-Related Proteins in CNS Autoimmunity
por: Keller, Christian W., et al.
Publicado: (2017)

Platelets in Multiple Sclerosis: Early and Central Mediators of Inflammation and Neurodegeneration and Attractive Targets for Molecular Imaging and Site-Directed Therapy
por: Orian, Jacqueline M., et al.
Publicado: (2021)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Dual Function pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma
por: Bogen, Jan P., et al.
Publicado: (2019)

The prevalence of IgG antibodies against milk and milk antigens in patients with multiple sclerosis
por: Chunder, Rittika, et al.
Publicado: (2023)

Fatty Acid Metabolism and T Cells in Multiple Sclerosis
por: Pompura, Saige L., et al.
Publicado: (2022)

Smoking Attributable Risk in Multiple Sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2022)

Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination
por: Repáraz, David, et al.
Publicado: (2022)

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
por: de Sèze, Jérôme, et al.
Publicado: (2023)

The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis
por: ‘T Hart, Bert A., et al.
Publicado: (2013)

Impact of complement activation on clinical outcomes in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2021)

B cell depletion therapy does not resolve chronic active multiple sclerosis lesions
por: Maggi, Pietro, et al.
Publicado: (2023)

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis
por: Hegen, Harald, et al.
Publicado: (2018)

Case Report: Antibodies to the N-Methyl-D-Aspartate Receptor in a Patient With Multiple Sclerosis
por: Zhou, Ran, et al.
Publicado: (2021)

Involvement of CD8(+) T Cells in Multiple Sclerosis
por: Salou, Marion, et al.
Publicado: (2015)

The Ins and Outs of B Cells in Multiple Sclerosis
por: Blauth, Kevin, et al.
Publicado: (2015)

Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies
por: Melamed, Esther, et al.
Publicado: (2020)

Long-Lived Plasma Cells in Autoimmunity: Lessons from B-Cell Depleting Therapy
por: Mahévas, Matthieu, et al.
Publicado: (2013)

Vitamin D/CD46 Crosstalk in Human T Cells in Multiple Sclerosis
por: Killick, Justin, et al.
Publicado: (2020)

The Influence of B Cell Depletion Therapy on Naturally Acquired Immunity to Streptococcus pneumoniae
por: Ercoli, Giuseppe, et al.
Publicado: (2021)

Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups
por: Donninelli, Gloria, et al.
Publicado: (2021)

Development of oral immunomodulatory agents in the management of multiple sclerosis
por: Nicholas, Richard, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0r5i5e2o2vr6o7qa8f2ej44vg2